Cargando…

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform

OBJECTIVE: To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. METHODS: Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jokubaitis, Vilija G., Spelman, Tim, Lechner-Scott, Jeannette, Barnett, Michael, Shaw, Cameron, Vucic, Steve, Liew, Danny, Butzkueven, Helmut, Slee, Mark, on behalf of the Australian MSBase Study Group
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602083/ https://www.ncbi.nlm.nih.gov/pubmed/23527252 http://dx.doi.org/10.1371/journal.pone.0059694

Ejemplares similares

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
por: Lizak, Nathaniel, et al.
Publicado: (2020)

The MSBase pregnancy, neonatal outcomes, and women’s health registry
por: Jokubaitis, Vilija G., et al.
Publicado: (2021)

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
por: Rojas, Juan Ignacio, et al.
Publicado: (2015)

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
por: Spelman, Tim, et al.
Publicado: (2022)

Epigenome-wide association studies: current knowledge, strategies and recommendations
por: Campagna, Maria Pia, et al.
Publicado: (2021)

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
por: Campagna, Maria Pia, et al.
Publicado: (2022)

Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study
por: Verwaest on behalf of the Belgiun Multicentre study group, C
Publicado: (1997)

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
por: Barnett, Michael, et al.
Publicado: (2021)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes
por: Xavier, Alexandre, et al.
Publicado: (2023)

Predictors of disability worsening in clinically isolated syndrome
por: Jokubaitis, Vilija G, et al.
Publicado: (2015)

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
por: Meyniel, Claire, et al.
Publicado: (2012)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis
por: Jokubaitis, Vilija G, et al.
Publicado: (2013)

MS, pregnancy and COVID-19
por: Yam, Charmaine, et al.
Publicado: (2020)

Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism
por: Gresle, Melissa M., et al.
Publicado: (2012)

Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders
por: Lowe, G C, et al.
Publicado: (2013)

Increased risk of cervical dysplasia in females with autoimmune conditions—Results from an Australia database linkage study
por: Foster, Emma, et al.
Publicado: (2020)

Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells
por: Gresle, Melissa M, et al.
Publicado: (2020)

Phenotypic Description of the Spanish Multicentre Genetic Glaucoma Group Cohort
por: Milla, Elena, et al.
Publicado: (2017)

Treatment of Women with Multiple Sclerosis Planning Pregnancy
por: Krysko, Kristen M., et al.
Publicado: (2021)

Trends in utilisation of ultrasound by older Australians (2010–2019)
por: Gaget, Virginie, et al.
Publicado: (2023)

Long-Term Outcomes of Contemporary Percutaneous Coronary Intervention with the Xience Drug-Eluting Stent: Results from a Multicentre Australian Registry
por: Eccleston, David S., et al.
Publicado: (2022)

Utilisation of Intensive Foraging Zones by Female Australian Fur Seals
por: Hoskins, Andrew J., et al.
Publicado: (2015)

Whole exome sequencing identifies a mutation in thrombomodulin as the genetic cause of a suspected platelet disorder in a family with normal platelet function
por: Maclachlan, Annabel, et al.
Publicado: (2017)

COVID-19 mRNA vaccination in patients with previous myocarditis
por: Pieroni, Maurizio, et al.
Publicado: (2022)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

The EURISOL Project
por: Y. Blumenfeld on behalf of the EURISOL Design Study
Publicado: (04/0)

EURISOL Design Study : Towards an Ultimate ISOL Facility for Europe
por: Y. Blumenfeld on behalf of the EURISOL Design Study
Publicado: (04/0)

076 Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries
por: Group, P Study, et al.
Publicado: (2022)

Time Trends, Regional Variability and Seasonality Regarding the Incidence of Type 1 Diabetes Mellitus in Romanian Children Aged 0-14 Years, Between 1996 and 2015
por: Vlad, Adrian, et al.
Publicado: (2018)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

Primary healthcare utilisation by older Australians during the COVID‐19 pandemic
por: Bartholomaeus, Jonathan D., et al.
Publicado: (2021)

Trends in utilisation of plain X-rays by older Australians (2010–2019)
por: Gaget, Virginie, et al.
Publicado: (2022)

Discovery machines: accelerators for science, technology, health and innovation
por: Australian Academy of Sciences
Publicado: (2016)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bekg54ue33l7eh4m2pgsr8ff6f